Blog

RSS Feed
Posted by Michael Wonder on 09 Feb 2026

ICER releases evidence report on therapies for IgA nephropathy

9 February 2026 - All three therapies exhibit net health benefits, but uncertainties remain around the magnitude of long-term improvements ...

Read more →
Posted by Michael Wonder on 04 Oct 2022

Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement

4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...

Read more →
Posted by Michael Wonder on 04 Dec 2020

ICER opens nominations for new members of its voting panels

2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →